WaveMan
WaveMan · Company
DNTH · Dianthus Therapeutics, Inc. /De/
> Search tickers & screens ⌘K
LIVE
← All companies

DNTH Dianthus Therapeutics (DNTH) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001690585
Quote by TradingView
Form 144 · 8
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
177
13F, latest reported quarter
Conversions, 180 days
17
Codes C/M, not in net · $4.3M priced

What the filings say about DNTH

Insiders, 180 days
-$31.7M net sold
8 sellers · 17% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$26.2M
8 notices

Dianthus Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Dianthus Therapeutics, Inc. /DE/ insiders sold a net $31.7M of stock across 71 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
CARR EDWARD
CHIEF ACCOUNTING OFFICER
SELL
2026-09-18 SECtraded 2026-09-17
7,928
$796.2K
-20.4%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Mar 12, 2026.
  • The trade is 65.7% of the 12,072 shares held after it.
  • 1 other insider sold within 30 days.
  • 177 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF ACCOUNTING OFFICER CARR EDWARD sold about $796.2K of DNTH under a 10b5-1 plan on Sep 17, 2026; 1 other insider sold within 30 days and 177 funds added in the latest 13F quarter.
CARR EDWARD
CHIEF ACCOUNTING OFFICER
SELL
2026-09-18 SECtraded 2026-09-17
6,771
$686.4K
-20.4%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Mar 12, 2026.
  • The trade is 127.7% of the 5,301 shares held after it.
  • 1 other insider sold within 30 days.
  • 177 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF ACCOUNTING OFFICER CARR EDWARD sold about $686.4K of DNTH under a 10b5-1 plan on Sep 17, 2026; 1 other insider sold within 30 days and 177 funds added in the latest 13F quarter.
CARR EDWARD
CHIEF ACCOUNTING OFFICER
SELL
2026-09-18 SECtraded 2026-09-17
3,501
$358.5K
-20.4%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Mar 12, 2026.
  • The trade is 194.5% of the 1,800 shares held after it.
  • 1 other insider sold within 30 days.
  • 177 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF ACCOUNTING OFFICER CARR EDWARD sold about $358.5K of DNTH under a 10b5-1 plan on Sep 17, 2026; 1 other insider sold within 30 days and 177 funds added in the latest 13F quarter.
CARR EDWARD
CHIEF ACCOUNTING OFFICER
SELL
2026-09-18 SECtraded 2026-09-17
1,100
$113.5K
-20.4%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Mar 12, 2026.
  • The trade is 157.1% of the 700 shares held after it.
  • 1 other insider sold within 30 days.
  • 177 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF ACCOUNTING OFFICER CARR EDWARD sold about $113.5K of DNTH under a 10b5-1 plan on Sep 17, 2026; 1 other insider sold within 30 days and 177 funds added in the latest 13F quarter.
CARR EDWARD
CHIEF ACCOUNTING OFFICER
SELL
2026-09-18 SECtraded 2026-09-17
700
$73.1K
-20.4%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Mar 12, 2026.
  • 1 other insider sold within 30 days.
  • 177 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF ACCOUNTING OFFICER CARR EDWARD sold about $73.1K of DNTH under a 10b5-1 plan on Sep 17, 2026; 1 other insider sold within 30 days and 177 funds added in the latest 13F quarter.
71 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 66 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$31.7M over 180 days
-$23.7M over 90 days
below 91% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
177 funds bought in last quarter
more than 87% of Pharma & Biotech
Revenue
-67.3% year over year
below 84% of Pharma & Biotech
Margin
-7973.3% net margin
below 99% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
16.4% of the float short (float per yahoo 2026-10-26) · 8.3 days to cover · settled 2026-09-30
more than 88% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch DNTH

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+129.5%12M
-2%+81%+164%+247%2025-102025-122026-022026-042026-062026-082026-10 2026-08-07 · Garcia Marino sold $11.2M2026-03-12 · Garcia Marino sold $5.4M2026-03-31 · Savitz Ryan sold $5.0M2025-11-14 · Randhawa Simrat sold $4.2M2026-03-12 · Garcia Marino sold $3.5M2026-03-12 · Randhawa Simrat sold $2.8M2026-08-07 · Garcia Marino sold $2.6M2026-08-07 · Garcia Marino sold $2.4M2026-03-24 · Soteropoulos Paula sold $2.2M2026-03-12 · CARR EDWARD sold $1.9M2026-08-10 · Veness Adam M sold $1.8M2026-03-31 · Savitz Ryan sold $1.7M2026-03-31 · Savitz Ryan sold $1.6M2025-11-13 · Randhawa Simrat sold $1.6M2026-07-09 · Savitz Ryan sold $1.6M2026-06-01 · Randhawa Simrat sold $1.5M2026-06-17 · Veness Adam M sold $1.3M2026-03-12 · CARR EDWARD sold $1.3M2026-08-07 · Garcia Marino sold $1.1M2026-06-17 · Veness Adam M sold $1.1M2026-03-12 · Garcia Marino sold $1.1M2026-07-09 · Savitz Ryan sold $1.0M2025-11-13 · Randhawa Simrat sold $936.7K2025-12-04 · Savitz Ryan sold $903.6K2026-09-17 · CARR EDWARD sold $796.2K2026-04-09 · Savitz Ryan sold $738.8K2025-11-13 · Randhawa Simrat sold $700.7K2026-09-17 · CARR EDWARD sold $686.4K2026-03-31 · Savitz Ryan sold $618.6K2026-07-09 · Savitz Ryan sold $567.6K2026-06-01 · Randhawa Simrat sold $487.0K2026-06-01 · Randhawa Simrat sold $380.0K2026-09-17 · CARR EDWARD sold $358.5K2026-08-07 · Veness Adam M sold $355.8K2026-08-19 · Read Simon sold $326.6K2026-03-12 · CARR EDWARD sold $319.5K2026-08-10 · McGeorge Anne sold $303.5K2026-08-07 · Garcia Marino sold $279.0K2026-08-07 · Garcia Marino sold $258.9K2026-08-10 · McGeorge Anne sold $196.7K2026-03-31 · Savitz Ryan sold $196.0K2026-08-10 · McGeorge Anne sold $156.0K2026-09-17 · EDWARD CARR filed to sell $2.0M2026-09-01 · SIMRAT RANDHAWA filed to sell $2.4M2026-08-10 · ANNE M MCGEORGE filed to sell $844.1K2026-08-10 · ADAM VENESS filed to sell $1.8M2026-08-10 · Read Simon filed to sell $624.4K2026-08-07 · MARINO GARCIA filed to sell $13.6M2026-08-07 · ADAM VENESS filed to sell $421.3K2026-08-07 · MARINO GARCIA filed to sell $4.4M2026-07-09 · RYAN SAVITZ filed to sell $3.1M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns DNTH: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
8,199,893 sh
$799.3M
BlackRock, Inc.
4,123,822 sh
$402.0M
WELLINGTON MANAGEMENT GROUP LLP
3,229,882 sh
$314.8M
Fairmount Funds Management LLC
2,537,191 sh
$247.3M
STATE STREET CORP
2,357,440 sh
$229.8M

Congress trades in DNTH

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

DNTH planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
EDWARD CARR
Filed 2026-09-17
$2.0M
SIMRAT RANDHAWA
Filed 2026-09-01
$2.4M
ANNE M MCGEORGE
Filed 2026-08-10
$844.1K
ADAM VENESS
Filed 2026-08-10
$1.8M
Read Simon
Filed 2026-08-10
$624.4K

DNTH mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Advisor Biotechnology Fund
$78.1M position · as of 2026-07-31
3.5%
F/m Emerald Life Sciences Innovation ETF
$3.2M position · as of 2026-05-31
3.1%
ALPS Medical Breakthroughs ETF
$4.3M position · as of 2026-05-31
2.6%
Franklin Biotechnology Discovery Fund
$26.8M position · as of 2026-07-31
2.3%
NICHOLAS PARTNERS SMALL CAP GROWTH FUND
$2.5M position · as of 2026-06-30
1.3%
PGIM Jennison Health Sciences Fund
$17.7M position · as of 2026-05-29
1.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 4 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 2
2 active
2
Phase 3
2 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Marino Garcia
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$8.8M
$12.0M
$4.0M
+245%
n/a
2022
$667.6K
$507.1K
n/a
n/a
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $31.7M sold by insiders over 180 days, 177 funds added last quarter, $26.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

DNTH financials

Revenue growth
-67.3%
XBRL, annual
Net margin
-7973.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.0M
four quarters, 2025-01-01 to 2025-12-31
Net margin, TTM
-9,442%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$155.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-26.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-25.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-29.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-3.6%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$2.0M$6.2M$2.8M$6.4M
Operating income-$177.9M-$101.9M-$48.2M-$29.7M
Net income-$162.3M-$85.0M-$43.5M-$28.5M
EPS (diluted)-4.20-2.55-8.45-32.57
Operating cash flow-$129.1M-$78.2M-$36.9M-$29.1M
Cash$51.1M$22.8M$132.3M$15.4M
SEC XBRL, fiscal years, as known on 2026-10-27

DNTH Stock Sonar score 5/7 axes

Find similar shapesCompare

DNTH ranks highest on institutional and government (87th percentile) and profitability (67th), and lowest on insider conviction (4th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
67
Inputs
  • Return on equity-26.1% · 69 pct, sector of 545
  • Return on assets-25.0% · 64 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-29.3% · 68 pct, sector of 576
Growth
16
Inputs
  • Revenue growth, YoY-67.3% · 16 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
4
Inputs
  • Net Form 4 buying (codes P and S), 180d-$29.3M · 7 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
87
Inputs
  • Funds adding, latest quarter177 · 87 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
41
Inputs
  • Short interest, % of float+16.4% · 22 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+8.8% · 59 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

DNTH filings, in plain words

Are Dianthus Therapeutics insiders buying or selling DNTH?

In the 180 days to 2026-10-27, Dianthus Therapeutics insiders were net sellers, a net $31.7M across purchases and sales reported on Form 4, by 8 sellers.

Are there planned insider sales of DNTH?

Yes. 8 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $26.2M of stock; the latest, by EDWARD CARR, was filed 2026-09-17.

Read the full summary

In the 180 days to 2026-10-27, Dianthus Therapeutics insiders were net sellers of DNTH, a net $31.7M across purchases and sales reported on Form 4 by 8 sellers. 17% of the 36 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 8 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $26.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies